Free Trial
→ Your book is inside (From Profits Run) (Ad)tc pixel Free GENF Stock Alerts

Genflow Biosciences (GENF) Competitors

Genflow Biosciences logo
GBX 2.13 +0.01 (+0.42%)
As of 06/5/2026 11:34 AM Eastern
Compare

GENF vs. POLB, COS, C4XD, DDDD, and SAR

Should you buy Genflow Biosciences stock or one of its competitors? MarketBeat compares Genflow Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Genflow Biosciences include Poolbeg Pharma (POLB), Collagen Solutions plc (COS.L) (COS), C4X Discovery (C4XD), 4D pharma (DDDD), and Sareum (SAR). These companies are all part of the "biotechnology" industry.

How does Genflow Biosciences compare to Poolbeg Pharma?

Genflow Biosciences (LON:GENF) and Poolbeg Pharma (LON:POLB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.

0.1% of Genflow Biosciences shares are held by institutional investors. Comparatively, 1.5% of Poolbeg Pharma shares are held by institutional investors. 47.5% of Genflow Biosciences shares are held by insiders. Comparatively, 7.6% of Poolbeg Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Genflow Biosciences has a net margin of 840.76% compared to Poolbeg Pharma's net margin of 0.00%. Genflow Biosciences' return on equity of 377.33% beat Poolbeg Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Genflow Biosciences840.76% 377.33% -58.66%
Poolbeg Pharma N/A -55.47%-21.33%

Poolbeg Pharma is trading at a lower price-to-earnings ratio than Genflow Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genflow BiosciencesN/AN/A-£1.76M-£0.33N/A
Poolbeg PharmaN/AN/A-£4.50B-£0.94N/A

Genflow Biosciences has a beta of 2.108, meaning that its share price is 111% more volatile than the broader market. Comparatively, Poolbeg Pharma has a beta of 1.775, meaning that its share price is 78% more volatile than the broader market.

In the previous week, Genflow Biosciences and Genflow Biosciences both had 1 articles in the media. Poolbeg Pharma's average media sentiment score of 0.75 beat Genflow Biosciences' score of 0.00 indicating that Poolbeg Pharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Genflow Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Poolbeg Pharma
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Genflow Biosciences beats Poolbeg Pharma on 7 of the 10 factors compared between the two stocks.

How does Genflow Biosciences compare to Collagen Solutions plc (COS.L)?

Genflow Biosciences (LON:GENF) and Collagen Solutions plc (COS.L) (LON:COS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.

Genflow Biosciences has a net margin of 840.76% compared to Collagen Solutions plc (COS.L)'s net margin of 0.00%. Genflow Biosciences' return on equity of 377.33% beat Collagen Solutions plc (COS.L)'s return on equity.

Company Net Margins Return on Equity Return on Assets
Genflow Biosciences840.76% 377.33% -58.66%
Collagen Solutions plc (COS.L) N/A N/A N/A

Collagen Solutions plc (COS.L) has higher revenue and earnings than Genflow Biosciences. Genflow Biosciences is trading at a lower price-to-earnings ratio than Collagen Solutions plc (COS.L), indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genflow BiosciencesN/AN/A-£1.76M-£0.33N/A
Collagen Solutions plc (COS.L)£4.01M0.00N/A-£0.80N/A

In the previous week, Genflow Biosciences had 1 more articles in the media than Collagen Solutions plc (COS.L). MarketBeat recorded 1 mentions for Genflow Biosciences and 0 mentions for Collagen Solutions plc (COS.L). Genflow Biosciences' average media sentiment score of 0.00 equaled Collagen Solutions plc (COS.L)'saverage media sentiment score.

Company Overall Sentiment
Genflow Biosciences Neutral
Collagen Solutions plc (COS.L) Neutral

0.1% of Genflow Biosciences shares are held by institutional investors. 47.5% of Genflow Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Genflow Biosciences beats Collagen Solutions plc (COS.L) on 7 of the 9 factors compared between the two stocks.

How does Genflow Biosciences compare to C4X Discovery?

C4X Discovery (LON:C4XD) and Genflow Biosciences (LON:GENF) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

In the previous week, Genflow Biosciences had 1 more articles in the media than C4X Discovery. MarketBeat recorded 1 mentions for Genflow Biosciences and 0 mentions for C4X Discovery. C4X Discovery's average media sentiment score of 0.00 equaled Genflow Biosciences'average media sentiment score.

Company Overall Sentiment
C4X Discovery Neutral
Genflow Biosciences Neutral

C4X Discovery has a beta of 0.23, meaning that its share price is 77% less volatile than the broader market. Comparatively, Genflow Biosciences has a beta of 2.108, meaning that its share price is 111% more volatile than the broader market.

Genflow Biosciences has a net margin of 840.76% compared to C4X Discovery's net margin of 42.81%. Genflow Biosciences' return on equity of 377.33% beat C4X Discovery's return on equity.

Company Net Margins Return on Equity Return on Assets
C4X Discovery42.81% 55.38% 28.04%
Genflow Biosciences 840.76%377.33%-58.66%

C4X Discovery has higher revenue and earnings than Genflow Biosciences. Genflow Biosciences is trading at a lower price-to-earnings ratio than C4X Discovery, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
C4X Discovery£24.68M0.00£10.57M£0.04N/A
Genflow BiosciencesN/AN/A-£1.76M-£0.33N/A

52.1% of C4X Discovery shares are owned by institutional investors. Comparatively, 0.1% of Genflow Biosciences shares are owned by institutional investors. 27.1% of C4X Discovery shares are owned by company insiders. Comparatively, 47.5% of Genflow Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

C4X Discovery beats Genflow Biosciences on 6 of the 11 factors compared between the two stocks.

How does Genflow Biosciences compare to 4D pharma?

4D pharma (LON:DDDD) and Genflow Biosciences (LON:GENF) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, earnings and analyst recommendations.

Genflow Biosciences has a net margin of 840.76% compared to 4D pharma's net margin of 0.00%. Genflow Biosciences' return on equity of 377.33% beat 4D pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
4D pharmaN/A -89.48% -42.64%
Genflow Biosciences 840.76%377.33%-58.66%

In the previous week, Genflow Biosciences had 1 more articles in the media than 4D pharma. MarketBeat recorded 1 mentions for Genflow Biosciences and 0 mentions for 4D pharma. 4D pharma's average media sentiment score of 0.00 equaled Genflow Biosciences'average media sentiment score.

Company Overall Sentiment
4D pharma Neutral
Genflow Biosciences Neutral

4D pharma has a beta of 2.63, meaning that its share price is 163% more volatile than the broader market. Comparatively, Genflow Biosciences has a beta of 2.108, meaning that its share price is 111% more volatile than the broader market.

Genflow Biosciences has lower revenue, but higher earnings than 4D pharma. Genflow Biosciences is trading at a lower price-to-earnings ratio than 4D pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
4D pharma£718K0.00-£31.94M-£15.40N/A
Genflow BiosciencesN/AN/A-£1.76M-£0.33N/A

26.8% of 4D pharma shares are held by institutional investors. Comparatively, 0.1% of Genflow Biosciences shares are held by institutional investors. 12.2% of 4D pharma shares are held by company insiders. Comparatively, 47.5% of Genflow Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Genflow Biosciences beats 4D pharma on 6 of the 11 factors compared between the two stocks.

How does Genflow Biosciences compare to Sareum?

Genflow Biosciences (LON:GENF) and Sareum (LON:SAR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

0.1% of Genflow Biosciences shares are owned by institutional investors. 47.5% of Genflow Biosciences shares are owned by insiders. Comparatively, 35.9% of Sareum shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Genflow Biosciences has a net margin of 840.76% compared to Sareum's net margin of 0.00%. Genflow Biosciences' return on equity of 377.33% beat Sareum's return on equity.

Company Net Margins Return on Equity Return on Assets
Genflow Biosciences840.76% 377.33% -58.66%
Sareum N/A -284.01%-113.80%

Genflow Biosciences is trading at a lower price-to-earnings ratio than Sareum, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genflow BiosciencesN/AN/A-£1.76M-£0.33N/A
SareumN/AN/A-£5.28M-£3.90N/A

Genflow Biosciences has a beta of 2.108, indicating that its stock price is 111% more volatile than the broader market. Comparatively, Sareum has a beta of -1.08, indicating that its stock price is 208% less volatile than the broader market.

In the previous week, Genflow Biosciences had 1 more articles in the media than Sareum. MarketBeat recorded 1 mentions for Genflow Biosciences and 0 mentions for Sareum. Genflow Biosciences' average media sentiment score of 0.00 equaled Sareum'saverage media sentiment score.

Company Overall Sentiment
Genflow Biosciences Neutral
Sareum Neutral

Summary

Genflow Biosciences beats Sareum on 9 of the 10 factors compared between the two stocks.

Get Genflow Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for GENF and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GENF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GENF vs. The Competition

Export
MetricGenflow BiosciencesBiotechnology IndustryMedical SectorLON Exchange
Market Cap£11.43M£460.38M£6.68B£2.50B
Dividend YieldN/A3.87%2.67%6.12%
P/E Ratio-6.433.1524.03365.23
Price / SalesN/A6,606.57519.3387,121.98
Price / Cash3.0013.1342.2327.85
Price / Book8.6083.479.737.68
Net Income-£1.76M-£96.07M£3.57B£5.89B
7 Day Performance1.62%-1.89%-1.26%-0.50%
1 Month Performance-19.77%1.04%0.82%2.10%
1 Year Performance149.30%64.50%24.09%72.87%

Genflow Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GENF
Genflow Biosciences
N/AGBX 2.13
+0.4%		N/A+142.5%£11.43MN/AN/A5
POLB
Poolbeg Pharma
N/AGBX 5.52
+9.4%		N/A+138.9%£38.89MN/AN/A12
COS
Collagen Solutions plc (COS.L)
N/AN/AN/AN/A£30.99M£4.01MN/A3,350
C4XD
C4X Discovery
N/AN/AN/AN/A£30.27M£24.68M300.0049
DDDD
4D pharma
N/AN/AN/AN/A£30.05M£718KN/A106

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:GENF) was last updated on 6/6/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
BUY THIS: Claim a backdoor stake in SpaceX before June 12
Marc Chaikin, the Wall Street veteran who spotted Nvidia before a 45,000% run, says there's a simple trade ava...
Chaikin Analytics | Sponsoredtc pixel
One hidden supplier shipped 5 billion parts to SpaceX
Most investors are focused on the historic $1.75 trillion SpaceX IPO expected around June 30. But there's a le...
Weiss Ratings | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
I paid $5,000 to hear Elon say this
One investor paid $5,000 to be in a private room with Elon Musk in Los Angeles - and what he heard confirmed a...
InvestorPlace | Sponsoredtc pixel
How to get into the SpaceX IPO before June 12
Former tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their h...
Brownstone Research | Sponsoredtc pixel
Goldman Sachs just told you what to buy (most people missed it)
Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...
Behind the Markets | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel